Strategic Collaborations

By partnering and collaborating with various organizations, we are able to strengthen our drug development operations. We are seeking collaborators to maximize the full potential of our lead candidate and licensing opportunities to complement our current platform. Please send business development inquiries via our Contact Us page.

Amplity Health

In February 2021, we announced a partnership with Amplity Health, a leading global contract commercialization organization, to support the anticipated U.S. commercialization of Brexafemme, the conditionally FDA-approved brand name for ibrexafungerp for vaginal yeast infections, in the second half of 2021. We will utilize Amplity’s commercial execution expertise and resources for sales force, remote engagement, training, market access and select operations services.

More information can be found here.

Hansoh Pharma

In February 2021, we announced a licensing and strategic partnership agreement for ibrexafungerp with Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, that covers the Greater China region. We received a $10 million upfront payment and are eligible to receive development and commercial milestone payments of up to $112 million, plus low double-digit royalties on net sales.

More information can be found here.

Merck

Ibrexafungerp (formerly SCY-078) was initially discovered at our research facilities and developed as part of a research collaboration with Merck. Subsequently, all worldwide intellectual property, development and commercialization rights were transferred to SCYNEXIS. We are currently developing this product as a novel oral and intravenous (IV) drug for the treatment of multiple serious and often life-threatening fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

R-Pharm

In August 2013, we announced an agreement with R-Pharm CJSC, a leading supplier of hospital drugs in Russia, granting them exclusive rights to develop and commercialize ibrexafungerp (formerly SCY-078) in Russia, Turkey and certain Balkan, Central Asian, Middle Eastern and Northern African countries. Invasive fungal infections are a serious health concern in these countries and we are pleased to be working with R-Pharm to develop ibrexafungerp for these patients.